Key regions: United Kingdom, Brazil, Europe, France, Canada
The demand for Anti-Fibrinolytic Drugs in Eastern Europe has been on the rise over the past few years.
Customer preferences: Eastern European countries have a high incidence of cardiovascular diseases, which has resulted in an increased demand for Anti-Fibrinolytic Drugs. Patients suffering from acute bleeding disorders, liver diseases, or undergoing surgeries often require these drugs to prevent excessive bleeding. Additionally, the rising geriatric population in the region has also contributed to the growth of the Anti-Fibrinolytic Drugs market.
Trends in the market: Russia is the largest market for Anti-Fibrinolytic Drugs in Eastern Europe, followed by Poland and Ukraine. The market is dominated by a few multinational pharmaceutical companies, with local players having a relatively small share. However, local players are slowly gaining traction by offering cheaper alternatives to the expensive imported drugs. The market is expected to grow further due to the increasing number of surgeries being performed in the region and the rising awareness about the benefits of Anti-Fibrinolytic Drugs.
Local special circumstances: The healthcare systems in Eastern European countries are largely state-funded, which means that the governments play a significant role in determining the availability and pricing of drugs. The pricing and reimbursement policies in these countries are often complex and vary from country to country, making it challenging for pharmaceutical companies to enter the market. Additionally, the lack of awareness about bleeding disorders and their treatment options among the general public has also hindered the growth of the Anti-Fibrinolytic Drugs market.
Underlying macroeconomic factors: The economic conditions in Eastern Europe have been improving steadily over the past few years, which has resulted in increased healthcare spending by governments. The rising disposable income of the middle class has also contributed to the growth of the Anti-Fibrinolytic Drugs market, as patients are now able to afford more expensive treatments. However, the ongoing COVID-19 pandemic has disrupted the healthcare systems in the region, leading to a temporary slowdown in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
